Aytu bioscience, inc (AYTU)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Feb'15Nov'14May'14Feb'14Nov'13Aug'13May'13Feb'13Nov'12Aug'12May'12Feb'12Nov'11Aug'11May'11Feb'11Nov'10
Net loss

-

-

-4,929

-

-

-

-3,446

546

-2,816

-3,672

-4,245

-6,750

-5,216

-4,817

-5,724

-15,297

-7,274

-3,332

-2,276

-9

-15

-11

-22

-16

-10

-13

-13

-19

-17

-11

-10

-19

-71

-20

-26

-17

Adjustments to reconcile net loss to cash used in operating activities
Issuance of restricted stock

-

-

-

-

-

-

-

-

54

31

72

69

498

81

75

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

68

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation, amortization and accretion

1,622

1,288

869

752

743

673

556

615

660

661

653

2,100

541

900

822

441

191

113

129

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense and restricted stock issuance

263

162

165

299

376

194

152

308

12

80

195

260

816

381

1,043

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) / gain from change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

16

266

-70

37

27

-78

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of prepaid research and development - related party (Note 9)

-

-

-

-

-

-

-

-

-

-

-

0

274

30

30

30

30

30

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on investment

-

-

-

-

-

-

-

-

-

-

-

-

-292

-497

728

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Compensation through issuance of stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock to employee

-

-

-

-

-

-

-

-

-

-

-

0

0

0

509

-

0

0

0

-

-

-

-

-

2

0

0

0

0

0

0

0

60

0

0

0

Derivative income

0

0

1

15

-2

20

47

26

3,139

518

299

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of warrants to initial investors

-

-

-

-

-

-

-

-

-

-

-

0

0

7

589

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

Contributed capital to fund expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

1

-

0

1

-

-

-

2

3

1

0

1

1

0

1

0

Changes in operating assets and liabilities:
(Increase) in accounts receivable

4,727

3,491

-35

364

-106

722

181

-153

-644

165

683

174

-239

72

347

78

-204

120

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Increase) in inventory

213

191

-59

-90

-114

334

-28

455

-495

208

-140

95

-205

-146

60

-96

-31

159

454

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Increase) in prepaid expenses and other

1,440

556

-384

152

-139

207

296

-456

131

503

-48

-31

-94

-116

337

-727

201

381

-10

-6

-0

-0

0

-0

-0

0

0

-0

-0

0

0

-0

-0

0

0

0

(Increase) decrease in security deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

(Decrease) in accounts payable and other

-7,719

2,530

276

326

-443

260

-7

-1,077

-156

1,684

-559

801

-112

-86

-109

648

176

-5

-121

1

3

-19

11

7

1

-5

3

7

0

2

-0

5

-1

1

-2

3

Increase in accrued liabilities

6,615

142

3

203

-2

517

242

-25

-46

-645

120

-268

92

260

-498

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in accrued compensation

334

-215

152

57

47

-53

256

-357

60

156

340

-505

326

-12

-668

412

295

-124

420

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in interest payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

57

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Decrease) in deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

1

1

-0

-0

-0

1

-11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Decrease) in deferred rent

-

0

-3

-

-

0

-1

-1

-1

-1

-1

-

-

-

-

-447

-21

-21

-21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-11,522

-6,099

-2,987

-3,473

-3,310

-4,302

-2,744

-4,543

-4,078

-3,100

-4,217

-

-

-

-

-

-

-

-

-13

-9

-14

-8

-6

-5

-15

-8

-8

-12

-5

-8

-11

-9

-17

-26

-11

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-2,392

-2,836

-5,332

-2,664

-2,385

-3,449

-2,157

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows used in investing activities
Deposit

0

0

0

0

0

0

-2

2

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of fixed assets

0

0

0

0

46

6

6

0

62

12

0

58

8

40

4

49

78

121

3

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Contingent consideration payment

47

62

42

96

358

50

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Notes receivable

-

350

1,000

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of assets

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of assets

1,350

4,500

0

0

-300

500

300

-

-

-

-

0

0

250

500

500

0

540

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

343

-4,912

-1,042

-96

-105

-557

-303

-402

-69

-12

0

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-1,278

-2,290

-504

-4,562

-78

-659

-3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock to Lincoln Park

-

-

-

-

-

-

-

-

-

-

-

108

0

0

631

0

0

0

0

0

15

17

0

0

0

0

0

5

0

4

7

5

12

6

19

5

Issuance costs related to preferred, common stock and warrants

-

-

-

-

-

-

-

-

-

-

-

66

0

0

24

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of preferred, common stock and warrants

-

-

-

-

-

-

-

-12,900

12,900

0

11,839

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance costs related to preferred, common stock and warrants

-

-

-

-

-

-

-

-1,294

1,294

0

1,402

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition costs included in accounts payable

-

-

59

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Exchange of convertible preferred stock into common stock

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued to investors and underwriters (see Note 6)

-

-

-

-

-

-

-

-

0

0

4,117

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earn-out payment to Nuelle Shareholders

-

-

-

-

-

-

-

0

0

238

11

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8

6

8

-0

-1

1

-2

2

0

0

-0

-0

-2

-3

0

5

-0

Cash paid during the period for Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Cash paid during the period for Interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

2

0

0

0

Proceeds from convertible promissory notes, net (Note 8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5,175

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt issuance costs (Note 8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

298

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from convertible note from Ampio converted to stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

1

5

8

5

3

12

10

4

12

0

0

3

3

14

11

6

Fixed assets included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-47

-2

-34

95

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on related party loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

1

10

2

0

0

Net cash provided by financing activities

68,183

9,258

0

116

258

18,700

0

-23

12,246

0

10,437

-

-

-

-

-

-

-

-

4

16

23

8

5

6

12

10

9

12

5

7

8

6

18

31

11

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

1,910

7,607

607

6,615

170

5,000

4,876

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, restricted cash and cash equivalents

57,005

-1,753

-4,029

-3,453

-3,157

13,840

-3,047

-4,969

8,098

-3,113

6,219

-2,667

-1,760

2,481

-5,229

-611

-2,293

890

2,715

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of cash and non-cash investing and financing transactions
Cash paid for interest

230

158

3

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of right-to-use asset and related lease liability

-19

-38

412

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contingent consideration included in accounts payable

11

12

3

13

29

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Primsol accretion included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fixed assets included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-47

-2

-34

95

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

102

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Primsol asset purchase included in Primsol payable, $1,250,000 less future accretion of $173,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

60

0

0

0